Harvard Bioscience (HBIO) Receivables (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Receivables data on file, last reported at $14.6 million in Q1 2026.

• Receivables for Q1 2026 came in at $14.6 million, up 8.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.6 million (up 8.11% YoY), and the FY2025 annual result was $16.0 million, up 7.92% from the prior year.
• Receivables fell to $14.6 million in Q1 2026 per HBIO's latest filing, from $16.0 million in the prior quarter.
• Over five years, Receivables peaked at $20.3 million in Q1 2022 and troughed at $11.9 million in Q2 2025.
• A 5-year average of $15.2 million and a median of $15.0 million in 2022 frame the typical range for Receivables.
• The sharpest annual moves came in 2022 and 2024: Receivables increased 18.74% in 2022, then slipped 26.13% in 2024.
• A 5-year view of Receivables shows it stood at $16.7 million in 2022, then decreased by 3.63% to $16.1 million in 2023, then slipped by 7.66% to $14.9 million in 2024, then increased by 7.92% to $16.0 million in 2025, then slipped by 9.17% to $14.6 million in 2026.
• Business Quant data shows HBIO's Receivables at $14.6 million in Q1 2026, $16.0 million in Q4 2025, and $12.1 million in Q3 2025.